Bluejay Diagnostics Inc (BJDX)
Bluejay Diagnostics, Inc. is a medical diagnostics company whose common stock is listed on the NASDAQ under the ticker BJDX. The company develops the Symphony technology platform, which includes an analyzer and single-use protein detection cartridges designed to measure diagnostic biomarkers in blood. Its analyzer is used to support sample processing across whole blood, plasma, serum, and related specimen types, including biomarker isolation and immunoassay preparation through non-contact centrifugal force. Bluejay Diagnostics is also developing Symphony IL-6 tests for tracking disease progression in critical care settings, along with additional assays for indications such as myocardial infarction and congestive heart failure. Incorporated in 2015, the company is headquartered in Acton, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BJDX
|
$1.22
|
7.1% Upside
|
Fair
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-0.2x
|
0.3x
|
—
|
1.252 M
|
-2.41 M
|
7.8%
|
85.0%
|
-24.3
|
—
|
96.3%
|
